Progress in ASC30 Research
September 17, 2025
Source: drugdu
91
On September 17, Ascletis Pharma-B (01672) issued an announcement, announcing that it reported the results of a 28-day multiple-dose escalation study of its ASC30 oral small molecule GLP-1R agonist at the 61st European Association for the Study of Diabetes Annual Meeting held in Vienna, Austria on September 16, 2025.
In MAD Cohort 2, once-daily oral administration of ASC30 demonstrated a placebo-adjusted mean weight loss of 6.5% from baseline after 28 days of treatment, compared to a mean weight loss of 4.5% in MAD Cohort 1. The study was well-safe and well-tolerated, with only mild to moderate gastrointestinal adverse events and no serious adverse events.
https://finance.eastmoney.com/a/202509173515879467.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
